Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Share-based Compensation (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Share-based Compensation for 17 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 18.37% to $5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.6 million through Dec 2025, down 23.77% year-over-year, with the annual reading at $18.6 million for FY2025, 23.77% down from the prior year.
  • Share-based Compensation hit $5.8 million in Q4 2025 for Integra Lifesciences Holdings, up from $5.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $15.7 million in Q2 2021 to a low of $1.9 million in Q1 2025.
  • Historically, Share-based Compensation has averaged $6.4 million across 5 years, with a median of $5.8 million in 2023.
  • Biggest five-year swings in Share-based Compensation: soared 203.54% in 2021 and later crashed 66.6% in 2025.
  • Year by year, Share-based Compensation stood at $6.4 million in 2021, then fell by 10.9% to $5.7 million in 2022, then grew by 1.08% to $5.8 million in 2023, then grew by 23.46% to $7.2 million in 2024, then fell by 18.37% to $5.8 million in 2025.
  • Business Quant data shows Share-based Compensation for IART at $5.8 million in Q4 2025, $5.6 million in Q3 2025, and $5.3 million in Q2 2025.